Form 4: VolitionRx CEO's RSU Tax Withholding Reported

VolitionRx's CEO of Veterinary, Salvatore Thomas Butera, had 4,648 shares withheld for tax obligations upon restricted stock unit settlement.

Summary

• Salvatore Thomas Butera, CEO of Volition Veterinary, reported a transaction on November 1, 2025.
• 4,648 shares of VolitionRx Common Stock were retained by the company for cancellation to satisfy tax withholding obligations.
• This withholding was upon the settlement of 16,996 restricted stock units (RSUs) awarded to Mr. Butera.
• The deemed price for the shares withheld was $0.434.
• No shares were sold by Mr. Butera or VolitionRx in this transaction; it was solely for tax purposes.
• Following the transaction, Mr. Butera directly beneficially owns 321,803 shares and jointly owns 99,350 shares with his spouse.

Sentiment

Score: 5

Explanation: The transaction is a routine tax withholding event related to the settlement of restricted stock units, reflecting standard executive compensation practices rather than a discretionary sale or purchase.

Positives

• Settlement of 16,996 restricted stock units (RSUs) indicates compensation for the CEO, reflecting performance or tenure.

Negatives

• 4,648 shares of common stock were withheld for tax purposes, resulting in a reduction of direct beneficial ownership.

Related Party Transactions

• The transaction involves the settlement of restricted stock units (RSUs) awarded to the CEO by VolitionRx, which is a related-party compensation event.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax withholding event related to executive compensation.
• Employees: Reflects standard executive compensation practices.

Key Dates

Recommendation

This Form 4 reports a routine tax withholding transaction related to the settlement of restricted stock units for an executive. It does not indicate any discretionary buying or selling activity that would suggest a change in the company's fundamental outlook or warrant a revised investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing provides no new material information to alter an existing investment thesis.

Keywords

VNRX, VolitionRx, Form 4, Insider Transaction, Restricted Stock Units, RSU, Tax Withholding, Salvatore Thomas Butera, CEO, Veterinary